Differences between 99mTc-sestamibi and 99mTc- tetrofosmin uptake in thyroid and salivary glands: Comparison with 99mTc-pertechnetate in 86 subjects

Nuclear Medicine Communications

Volumn 24, Issue 3, 2003, Pages 321-326

  Giordano, A ^a   Meduri, G ^a   Marozzi, P ^b   Rubini, G ^c   Burroni, L ^d   Cappagli, M ^e  

^a FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^b VILLA SOFIA CERVELLO HOSPITAL   (Italy)

^c UNIVERSITY OF BARI   (Italy)

^d UNIVERSITY HOSPITAL OF SIENA   (Italy)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Parathyroid scintigraphy; Salivary gland scintigraphy; Thyroid scintigraphy

Indexed keywords

DIAGNOSTIC AGENT; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; ORGANOPHOSPHORUS COMPOUND; PERTECHNETIC ACID TC 99M; RADIOPHARMACEUTICAL AGENT; TECHNETIUM COMPLEX; TECHNETIUM TC 99M 1,2 BIS(BIS(2 ETHOXYETHYL)PHOSPHINO)ETHANE; TECHNETIUM TC 99M 1,2-BIS(BIS(2-ETHOXYETHYL)PHOSPHINO)ETHANE;

ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; HUMAN; HYPERPARATHYROIDISM; ITALY; METABOLISM; MULTICENTER STUDY; REPRODUCIBILITY; SALIVARY GLAND; SCINTISCANNING; THYROID GLAND; TISSUE DISTRIBUTION; TRANSPORT AT THE CELLULAR LEVEL;

BIOLOGICAL TRANSPORT; HUMANS; HYPERPARATHYROIDISM; ITALY; ORGANOPHOSPHORUS COMPOUNDS; ORGANOTECHNETIUM COMPOUNDS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SALIVARY GLANDS; SODIUM PERTECHNETATE TC 99M; TECHNETIUM TC 99M SESTAMIBI; THYROID GLAND; TISSUE DISTRIBUTION;

EID: 85047688395     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/00006231-200303000-00013     Document Type: Article

References (35)

1. Soman P, Taillefer R, DePuey EG, Udelson JE, Lahiri A. Enhanced detection of reversible perfusion defects by Tc-99m Sestamibi compared to Tc-99m Tetrofosmin during vasodilator stress SPECT imaging in mild-to-moderate coronary artery disease. J Am Coll Cardiol 2001; 37: 458-462.
2. 99mTc-Medronate incorporation. Anticancer Res 1999; 19: 255-259.
3. 99mTc-tetrofosmin into malignant versus nonmalignant breast cell lines. J Nucl Med 2000; 41: 1495-1499.
4. Fjeld JG, Erichsen K, Pfeffer PF, Ole PF, Rootwelt C, Rootwelt K. Technetium-99m-Tetrofosmin for parathyroid scintigraphy: a comparison with sestamibi. J Nucl Med 1997; 38: 831-834.
5. Mansi L, Rambaldi PF, Marino G, Pecori B, Del Vecchio E. Kinetics of Tc99m-Sestamibi and Tc99m-Tetrofosmin in a case of parathyroid adenoma. Clin Nucl Med 1996; 21: 700-703.
6. Giordano A, Meduri G. Differences between Technetium-99m tetrofosmin and Technetium-99m sestamibi in parathyroid scintigraphy. Eur J Nucl Med 1997; 24: 347 (letter).
7. Kostakoglu L, Uysal U, Ozyar E, et al. A comparative study of technetium-99m sestamibi and technetium-99m tetrofos-min single-photon tomography in the detection of nasopharyngeal carcinoma. Eur J Nucl Med 1997; 24: 621-628.
8. Giordano A, Rubello D, Casara D. New trends in parathyroid scintigraphy. Eur J Nucl Med 2001; 28: 1409-1420.
9. Ishibashi M, Nishida H, Strauss W, et al. Localization of parathyroid glands using technetium-99m-tetrofosmin imaging. J Nucl Med 1997; 38: 834-839.
10. 99mTc-Sestamibi parathyroid scintigraphy: effect of P-glycoprotein, histology and tumor size on detectability. J Nucl Med 1998; 39: 1617-1620.
11. 99mTc-MIBI uptake and oxyphil cell content. J Nucl Med 1998; 39: 1441-1444.
12. 99mTc-Sestamibi uptake and oxyphil cell content in hyper-parathyroidism? Eur J Nucl Med 1999; 40:1403-1404 (letter).
13. 99mTc-MIBI scan: semiquantitative analysis correlated with histologic findings. J Nucl Med 1999; 40: 1792-1797.
14. Takami H, Oshima M, Sugawara I, et al. Pre-operative localization and tissue uptake study in parathyroid imaging with Technetium-99m-Sestamibi. Aust N Z Surg 1999; 69: 629-631.
15. Torregrosa JV, Fernandez-Cruz L, Canalejo A, et al. (99m)Tc-Sestamibi scintigraphy and cell cycle in parathyroid glands of secondary hyperparathyroidism. World J Surg 2000; 24: 1386-1390.
16. 99mTc-Tetrofosmin: a comparison with 201Thallium. Nucl Med Commun 1995; 16: 223 (abstract 48).
17. Giordano A, Meduri G, Marozzi P. Parathyroid imaging with Tc99m-Tetrofosmin. Nucl Med Commun 1996; 17: 706-710.
18. Giordano A, Marozzi P, Meduri G, et al. Quantitative comparison of Technetium-99m Tetrofosmin and thal-lium201 images of the thyroid and abnormal parathyroid glands. Eur J Nucl Med 1999; 26: 907-911.
19. Meduri G, Giordano A, Calcagni ML, Galli G. Reduced thyroid uptake and slower wash-out of tetrofosmin as compared to sestamibi in 64 normal subjects: an explanation of differences in parathyroid scintigraphy. Q J Nucl Med 1998; 42: 57 (abstract 205).
20. 99mTc-sestamibi in parathyroid scintigraphy. Results in 133 subjects. Eur J Nucl Med 1998; 25: 956 (abstract OS-480).
21. Apostolopoulos DJ, Houstoulaki E, Giannakenas C, et al. Technetium-99m-tetrofosmin for parathyroid scintigraphy: comparison to Thallium-Technetium scanning. J Nucl Med 1998; 39: 1433-1441.
22. 99mTc-Tetrofosmin scintigraphy in the diagnosis and localization of hyperfunctioning parathyroid glands. Clin Nucl Med 1999; 24: 959-964.
23. Lind P, Gallowitsch HJ, Langsteger W, Kresnik E, Mikosch P, Gomez I. Technetium-99m-tetrofosmin whole body scintigraphy in the follow-up of differentiated thyroid carcinoma. J Nucl Med 1997; 38: 348-352.
24. Bland JM, Altaian DG. Multiple significance tests: the Bonferroni method. Br Med J 1995; 310: 170.
25. Taillefer R, Boucher Y, Potvin C, Lambert R. Detection and location of parathyroid adenomas in patients with hyper-parathyroidism using a single radionuclide imaging procedure with technetium-99m-sestamibi (double-phase study). J Nucl Med 1992; 33: 1801-1807.
26. 99mTc Sestamibi parathyroid scintigraphy. In: Freeman L, ed. Nuclear medicine annual 1995. New York: Raven Press, 1995: 51-79.
27. Ishibashi M, Nishida H, Kumabe T, et al. Tc99m-tetrofos-min. A new tracer for parathyroid scintigraphy. Clin Nucl Med 1995; 20: 902-905.
28. Aigner RM, Feuger GF, Nicoletti R. Parathyroid scintigra-phy: comparison of Technetium-99m methoxyisobutyliso-nitrile and Technetium-99m Tetrofosmin studies. Eur J Nucl Med 1996; 23: 693-696.
29. Hishibashi M, Nishida H, Hiromatsu Y, Kojima K, Tabuchi E, Hayabuchi N. Comparison of technetium-99m-MIBI, technetium-99m-tetrofosmin, ultrasound, and MRI for localization of abnormal parathyroid glands. J Nucl Med 1988; 39: 320-324.
30. Arbab AS, Koizumi K, Hiraike S, Toyama K, Arai T, Araki T. Will thallium-201 replace gallium-67 in salivary gland scintigraphy? J Nucl Med 1996; 37: 1819-1823.
31. 201Thallium SPET. Nucl Med Commun 2000; 21: 277-284.
32. Campeau RJ, Reutherr WL, Wayne J. False-positive Tc-99m sestamibi examination for parathyroid adenoma in a case of asymmetrical salivary gland enlargement. Clin Nucl Med 1999; 24: 723-724.
33. 201Thallium chloride/Tc-99m-pertechnetate subtraction SPECT. Clin Nucl Med 1996; 21: 213-217.
34. Leitha T, Glaser C, Pruckmayer M, et al. Technetium-99m-MIBI in primary and recurrent head and neck tumors: contribution of bone SPECT image fusion. J Nucl Med 1998; 39: 1166-1171.
35. Chisin R. Nuclear medicine in head and neck oncology: reality and perspectives. J Nucl Med 1999; 40: 91-95. ,327-330